Immune ablation and stem-cell therapy in autoimmune disease: Clinical experience

In the past 5 years, around 350 patients have received haematopoietic stem cell (HSC) transplantation for an autoimmune disease, with 275 of these registered in an international data base in Basel under the auspices of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation(EBMT). Most patients had either a progressive form of multiple sclerosis (MS; n = 88) or scleroderma (now called systemic sclerosis; n = 55). Other diseases were rheumatoid arthritis (Ra n = 40), juvenile idiopathic arthritis (JIA; n = 30), systemic lupus erythematosus (SLE; n = 20), idiopathic thrombocytopenic purpura (ITP; n = 7) and others. The procedure-related mortality was around 9%, with between-disease differences, being higher in systemic sclerosis and JIA and lower in RA (one death only). Benefit has been seen in around two-thirds of cases. No one regimen was clearly superior to another, with a trend toward more infectious complications with more intense regimens. Prospective, controlled randomized trials are indicated and being planned.

Data e Risorse

Campo Valore
accessLevel public
bureauCode {009:25}
catalog_@context https://project-open-data.cio.gov/v1.1/schema/catalog.jsonld
catalog_@id https://healthdata.gov/data.json
catalog_conformsTo https://project-open-data.cio.gov/v1.1/schema
catalog_describedBy https://project-open-data.cio.gov/v1.1/schema/catalog.json
identifier https://healthdata.gov/api/views/bw4c-7fsg
issued 2025-07-14
landingPage https://healthdata.gov/d/bw4c-7fsg
modified 2025-09-06
programCode {009:032}
publisher National Institutes of Health
resource-type Dataset
source_datajson_identifier true
source_hash 5b986cdd211a59d36e0e76d4e92ed2b90fa98d3c07ba24ff978cf6143988fc55
source_schema_version 1.1
theme {NIH}
Gruppi
  • AmeriGEOSS
  • National Provider
  • North America
Tag
  • AmeriGEO
  • AmeriGEOSS
  • CKAN
  • GEO
  • GEOSS
  • National
  • North America
  • United States
  • autoimmune-diseases
  • hematopoietic-stem-cell
  • nih
  • stem-cell-transplantation
  • treatment-outcomes
isopen False
license_id notspecified
license_title License not specified
maintainer NIH
maintainer_email info@nih.gov
metadata_created 2025-09-24T14:51:26.888526
metadata_modified 2025-09-24T14:51:26.888533
notes In the past 5 years, around 350 patients have received haematopoietic stem cell (HSC) transplantation for an autoimmune disease, with 275 of these registered in an international data base in Basel under the auspices of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation(EBMT). Most patients had either a progressive form of multiple sclerosis (MS; n = 88) or scleroderma (now called systemic sclerosis; n = 55). Other diseases were rheumatoid arthritis (Ra n = 40), juvenile idiopathic arthritis (JIA; n = 30), systemic lupus erythematosus (SLE; n = 20), idiopathic thrombocytopenic purpura (ITP; n = 7) and others. The procedure-related mortality was around 9%, with between-disease differences, being higher in systemic sclerosis and JIA and lower in RA (one death only). Benefit has been seen in around two-thirds of cases. No one regimen was clearly superior to another, with a trend toward more infectious complications with more intense regimens. Prospective, controlled randomized trials are indicated and being planned.
num_resources 1
num_tags 13
title Immune ablation and stem-cell therapy in autoimmune disease: Clinical experience